qDSA Blood Flow Measurement for Liver Cancer

Overseen By Radiology Coordinators

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Wisconsin, Madison

Disqualifiers: Pregnancy, Kidney disease, Contrast allergy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

Duration: 1 hour

20 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver transarterial embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.

Research Team

Paul Laeseke, MD, PhD

Principal Investigator

UW School of Medicine and Public Health

Eligibility Criteria

This trial is for up to 20 people who are undergoing liver transarterial embolization, a treatment for liver tumors. Participants will have one study visit with follow-ups for data collection over six months.

Inclusion Criteria

Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule

Exclusion Criteria

Pregnancy or breastfeeding

Patients with a physical or psychological condition that would impair study participation

The patient is judged unsuitable for study participation by the Investigator for any other reason

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo transarterial embolization (TAE) of the liver with qDSA blood flow measurement

1 hour

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the procedure, with data collection and analysis

up to 6 months

Treatment Details

Interventions

• qDSA Blood Flow Measurement

Trial Overview The trial is testing qDSA, a new technique to measure blood flow during liver embolization procedures. It aims to help doctors verify the reduction in tumor blood supply by assessing flow before, during, and after treatment.

Participant Groups

Group I: Participants Undergoing TAE of the Liver Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

University of Wisconsin, Madison

Lead Sponsor

Trials

1,249

Recruited

3,255,000+

Siemens Medical Solutions

Industry Sponsor

Trials

26

Recruited

6,100+